130 related articles for article (PubMed ID: 29040918)
1. Tumor cryoablation in combination with natural killer cells therapy and Herceptin in patients with HER2-overexpressing recurrent breast cancer.
Liang S; Niu L; Xu K; Wang X; Liang Y; Zhang M; Chen J; Lin M
Mol Immunol; 2017 Dec; 92():45-53. PubMed ID: 29040918
[TBL] [Abstract][Full Text] [Related]
2. Combination of adoptive immunotherapy with Herceptin for patients with HER2-expressing breast cancer.
Kubo M; Morisaki T; Kuroki H; Tasaki A; Yamanaka N; Matsumoto K; Nakamura K; Onishi H; Baba E; Katano M
Anticancer Res; 2003; 23(6a):4443-9. PubMed ID: 14666732
[TBL] [Abstract][Full Text] [Related]
3. Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer.
Zhang JL; Yao Q; Chen Y Wang JH; Wang H; Fan Q; Ling R; Yi J; Wang L
Genet Mol Res; 2015 Mar; 14(1):2099-103. PubMed ID: 25867356
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy of percutaneous cryoablation combined with allogenic NK cell immunotherapy for advanced non-small cell lung cancer.
Lin M; Liang SZ; Wang XH; Liang YQ; Zhang MJ; Niu LZ; Chen JB; Li HB; Xu KC
Immunol Res; 2017 Aug; 65(4):880-887. PubMed ID: 28508945
[TBL] [Abstract][Full Text] [Related]
5. Phase I Trial of Expanded, Activated Autologous NK-cell Infusions with Trastuzumab in Patients with HER2-positive Cancers.
Lee SC; Shimasaki N; Lim JSJ; Wong A; Yadav K; Yong WP; Tan LK; Koh LP; Poon MLM; Tan SH; Ow SGW; Bharwani L; Yap YS; Foo MZQ; Coustan-Smith E; Sundar R; Tan HL; Chong WQ; Kumarakulasinghe NB; Lieow JLM; Koe PJX; Goh BC; Campana D
Clin Cancer Res; 2020 Sep; 26(17):4494-4502. PubMed ID: 32522887
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.
Samy N; Ragab HM; El Maksoud NA; Shaalan M
Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232
[TBL] [Abstract][Full Text] [Related]
7. Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells.
Reim F; Dombrowski Y; Ritter C; Buttmann M; Häusler S; Ossadnik M; Krockenberger M; Beier D; Beier CP; Dietl J; Becker JC; Hönig A; Wischhusen J
Cancer Res; 2009 Oct; 69(20):8058-66. PubMed ID: 19826050
[TBL] [Abstract][Full Text] [Related]
8. Prospective study of percutaneous cryoablation combined with allogenic NK cell immunotherapy for advanced renal cell cancer.
Lin M; Xu K; Liang S; Wang X; Liang Y; Zhang M; Chen J; Niu L
Immunol Lett; 2017 Apr; 184():98-104. PubMed ID: 28274792
[TBL] [Abstract][Full Text] [Related]
9. Improved Natural Killer cell activity and retained anti-tumor CD8(+) T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy.
Muraro E; Comaro E; Talamini R; Turchet E; Miolo G; Scalone S; Militello L; Lombardi D; Spazzapan S; Perin T; Massarut S; Crivellari D; Dolcetti R; Martorelli D
J Transl Med; 2015 Jun; 13():204. PubMed ID: 26116238
[TBL] [Abstract][Full Text] [Related]
10. Cryoablation combined with allogenic natural killer cell immunotherapy improves the curative effect in patients with advanced hepatocellular cancer.
Lin M; Liang S; Wang X; Liang Y; Zhang M; Chen J; Niu L; Xu K
Oncotarget; 2017 Oct; 8(47):81967-81977. PubMed ID: 29137237
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant immunotherapy enhances radiosensitivity through natural killer cell activation.
Chi CH; Wang YS; Yang CH; Chi KH
Cancer Biother Radiopharm; 2010 Feb; 25(1):39-45. PubMed ID: 20187795
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
Jerome L; Alami N; Belanger S; Page V; Yu Q; Paterson J; Shiry L; Pegram M; Leyland-Jones B
Cancer Res; 2006 Jul; 66(14):7245-52. PubMed ID: 16849573
[TBL] [Abstract][Full Text] [Related]
13. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.
Shak S
Semin Oncol; 1999 Aug; 26(4 Suppl 12):71-7. PubMed ID: 10482196
[TBL] [Abstract][Full Text] [Related]
14. Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer.
Kono K; Takahashi A; Ichihara F; Sugai H; Fujii H; Matsumoto Y
Cancer Res; 2002 Oct; 62(20):5813-7. PubMed ID: 12384543
[TBL] [Abstract][Full Text] [Related]
15. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
Sliwkowski MX; Lofgren JA; Lewis GD; Hotaling TE; Fendly BM; Fox JA
Semin Oncol; 1999 Aug; 26(4 Suppl 12):60-70. PubMed ID: 10482195
[TBL] [Abstract][Full Text] [Related]
16. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer: final results of the Retreatment after HErceptin Adjuvant trial.
Láng I; Bell R; Feng FY; Lopez RI; Jassem J; Semiglazov V; Al-Sakaff N; Heinzmann D; Chang J
Clin Oncol (R Coll Radiol); 2014 Feb; 26(2):81-9. PubMed ID: 24051172
[TBL] [Abstract][Full Text] [Related]
18. E-cadherin expression on human carcinoma cell affects trastuzumab-mediated antibody-dependent cellular cytotoxicity through killer cell lectin-like receptor G1 on natural killer cells.
Yamauchi C; Fujii S; Kimura T; Kuwata T; Wada N; Mukai H; Matsumoto N; Fukayama M; Ochiai A
Int J Cancer; 2011 May; 128(9):2125-37. PubMed ID: 21387286
[TBL] [Abstract][Full Text] [Related]
19. Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer.
Shao Y; Sun X; He Y; Liu C; Liu H
PLoS One; 2015; 10(7):e0133830. PubMed ID: 26207909
[TBL] [Abstract][Full Text] [Related]
20. Comparative analysis of innate immune system function in metastatic breast, colorectal, and prostate cancer patients with circulating tumor cells.
Santos MF; Mannam VK; Craft BS; Puneky LV; Sheehan NT; Lewis RE; Cruse JM
Exp Mol Pathol; 2014 Jun; 96(3):367-74. PubMed ID: 24731923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]